Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Hayman

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 29, 2025
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple MyelomaMatthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood Cancer Journal|March 30, 2026
Management of hematological toxicities after BCMA-directed CAR-T cell therapyJoselle Cook, Supriya Gupta, Nadine Abdallah, et al.
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Annals of Hematology|April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Blood|September 12, 2022
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significanceMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 29, 2025
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple MyelomaMatthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood Cancer Journal|March 30, 2026
Management of hematological toxicities after BCMA-directed CAR-T cell therapyJoselle Cook, Supriya Gupta, Nadine Abdallah, et al.
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Annals of Hematology|April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Blood|September 12, 2022
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significanceMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Pageof 8